Faculty
Mark Albers, MD, PhD
Assistant Professor of Neurology
Harvard Medical School;
Clinician Investigator and Assistant Professor of Neurology
Mass General Research Institute;
Assistant Neurologist
Massachusetts General Hospital

Mark Albers, MD, PhD, is a neurologist specializing in memory and olfactory disorders. He earned a PhD in organic chemistry from Harvard University, working in the laboratory of Stuart Schreiber, and an MD degree from the H.S.T. program of Harvard Medical School and M.I.T. He was an internal medicine resident for two years at Massachusetts General Hospital and then trained in neurology at Mass General, and Brigham and Women’s Hospital, where he was one of the first chief residents for the partners neurology residency program.

Following clinical training, he resumed basic research studies in the laboratory of Richard Axel and practiced behavioral neurology in the Memory Disorders Center at the Neurological Institute, affiliated with Columbia University. Following this training, he returned to Mass General where he sees outpatients in the Memory Disorders Unit and attends on the inpatient neurologic wards.

His clinical research is focused on devising sensitive probes of olfactory function as a possible biomarker for the early neurodegenerative diseases Alzheimer’s disease, Parkinson's disease, chronic traumatic encephalopathy, and traumatic brain injury as well as directly converting olfactory neuronal precursor cells from the nose into brain neurons to develop cell-based models of neurologic disease. His laboratory research aims to elucidate fundamental mechanisms of neurodegeneration and develop therapies that leverage insights from these pathologic insights. Current work is focused on repurposing FDA-approved drugs and experimental drugs for Alzheimer's disease, ALS, frontotemporal dementia, and traumatic brain injury. He is the PI of the NADALS basket trial to examine an FDA approved drug in Alzheimer’s and ALS. He is a faculty member of the Laboratory of Systems Pharmacology at the Harvard Medical School and the Program in Regulatory Sciences at the Harvard Medical School. He is the assistant director of the Massachusetts Center for Alzheimer’s Therapeutic Science and is a member of the Harvard Program in Therapeutic Science.

Planners
Elizabeth Albert, MD
Clinical Activity Manager
Optum Health Education

Sarah Chart, RN
Vice President
Optum Health Education

Sara Fleszar, PharmD, BCOP
Senior Clinical Pharmacist
Optum Health Solutions

Rebecca Gleason, RN, CCM
Activity Manager
Optum Health Education

Lisa Latts, MD, MSPH, MBA, FACP
Chief Medical Officer
Optum Behavioral Health Solutions & Optum Health Solutions
Optum Health Clinical Excellence
Optum

Disclosures of relevant financial relationships
In accordance with the Accreditation Council for Continuing Medical Education's (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, Optum Health Education (OHE) requires all those in control of educational content to disclose their financial relationships with ineligible companies within the prior 24 months. Ineligible companies are defined by the ACCME as companies whose primary business is producing, marketing, selling, re-selling, or distributing health care products used by or on patients. Individuals must disclose all financial relationships, regardless of the amount, with ineligible companies and regardless of their view of the relevance of the relationship to the education. OHE ensures that the content is independent of commercial bias.

Financial Relationship Key
 A-Advisory Board
 CT-Clinical Trial
 C-Consultant
 E-Employee
 G- Grant/Research Support or Funding
 I-Stocks and Other Ownership Interests 
 S-Speakers’ Bureau
 O-Other Financial or Material Support

Mark Albers, MD: Lilly (O); Sudo (A); Aromha (I); Merck (C)

All relevant financial relationships have been mitigated. 

The remaining faculty and planners have no financial relationships to disclose.